Chamara Jayesinghe

• Serve as Program Team Lead responsible for long-term portfolio strategy, program governance, and development execution across Celexor Bio and Kalexo Bio portfolio companies.
• Lead cross-functional portfolio planning activities integrating scientific, operational, financial, and competitive landscape insights into executive decision-making and strategic prioritization.
• Drive development strategy from due diligence through early development, enabling optimized clinical and operational planning across complex therapeutic programs.
• Partner with executive leadership and functional leaders to establish strategic objectives, portfolio priorities, resource allocation strategies, and organizational execution plans.
• Develop and operationalize governance frameworks, KPI tracking systems, and integrated program management processes supporting portfolio advancement and corporate objectives.
• Lead alliance execution and external partner engagement while serving as primary strategic interface across collaborating organizations.
• Build and foster high-performing cross-functional teams focused on accountability, alignment, operational rigor, and execution excellence.
• Proactively identify strategic, operational, and development risks while implementing mitigation and contingency planning frameworks.
• Accountable for managing budget/ long-range portfolio planning of >$100M (Kalexo Bio and Celexor Bio), financial forecasting, and resource allocation activities to enable portfolio optimization and strategic growth.
• Partner with executive leadership and communications teams to develop strategic messaging, stakeholder communications, and executive updates.
• Monitor and synthesize competitive landscape intelligence and emerging clinical data to inform evolving portfolio strategy and investment decisions.

• Advised venture-backed biotechnology NewCos on portfolio strategy, program governance, development planning, operational build-out, and organizational design.
• Evaluated therapeutic portfolios, competitive landscapes, commercialization opportunities, valuation scenarios, and strategic resource planning initiatives.
• Supported program leadership and portfolio management activities across cell therapy and advanced therapeutic programs.
• Delivered executive-level strategic recommendations to founders, and senior leadership teams regarding portfolio prioritization and operational execution.

• Built and led the company’s Program and Portfolio Management function, establishing portfolio governance, competitive intelligence, alliance management, market analysis, and operational execution capabilities across the organization.
• Directed strategic portfolio planning and cross-functional execution for IMT-009 and the company’s broader immunology and immuno-oncology pipeline.
• Served as a strategic advisor to executive leadership, enabling portfolio prioritization, tradeoff decisions, and long-range development planning.
• Led development and implementation of portfolio management best practices, operational frameworks, governance structures, budget management (~$30M) and integrated development processes.
• Functioned as a key integration point between executive leadership and program teams to ensure organizational alignment and strategic execution.

Director, BEAM-201 Program Leader (05/23-11/23)

Director, Program Management (07/22-05/23)
Associate Director, Program Management (02/21-07/22)

• Led BEAM-201, the first allogeneic guard-edited CAR-T program, through IND-enabling activities and transition into clinical development.
• Directed cross-functional strategic planning and execution across Beam’s early pipeline portfolio spanning immunology, oncology, hematology, and liver disease.
• Held enterprise-level accountability for program operations, timelines, integrated development plans, governance activities, and portfolio deliverables.
• Developed and implemented portfolio-level operational frameworks, reporting systems, governance processes, and strategic business cases supporting executive and board-level decision-making.
• Facilitated alignment across research, development, technical operations, regulatory, clinical, and executive leadership teams.
• Managed integrated development planning, target product profile development, resource prioritization, and risk mitigation strategies across multiple programs.
• Partnered with leadership to build and scale the Program Management function, including operational processes, portfolio management tools, and organizational best practices.
• Developed quarterly Board of Directors materials, portfolio reviews, and executive communications supporting strategic decision-making.
• Led organizational initiatives focused on inclusion, diversity, belonging, leadership development, and cross-functional collaboration.
• Mentored and developed associates while fostering a culture of accountability, innovation, and operational excellence.

• Managed strategic operational planning and portfolio operations activities across a global Translational Medicine organization supporting approximately 880 FTEs.
• Led enterprise-wide strategic initiatives, operational transformation efforts, and organizational optimization programs supporting complex drug development portfolios.
• Partnered closely with global functional leaders to identify organizational priorities, operational gaps, and strategic opportunities aligned with enterprise objectives.
• Directed strategic resource planning, financial governance, operational analytics, and budget management activities across global functions.
• Developed executive portfolio reviews, KPI tracking frameworks, operational dashboards, and strategic analyses supporting leadership decision-making.
• Led major organizational initiatives including cell and gene therapy infrastructure investment proposals, clinical operations optimization strategies, and laboratory consolidation initiatives.
• Implemented operational and financial process improvements resulting in approximately $7 million in combined savings across FTE planning, CAPEX, and operational spend.
• Partnered with Oncology Cell and Gene commercial teams to develop long-term strategic positioning and competitive assessments for Kymriah and emerging pipeline assets.
• Designed analytics and operational intelligence frameworks supporting portfolio benchmarking, organizational effectiveness, and strategic planning.
• Coached and mentored colleagues on strategic initiatives, operational excellence, and sustainable organizational improvements.
• Led organizational culture and engagement initiatives supporting leadership alignment, collaboration, and workforce development

• Supported portfolio governance, strategic planning, and operational execution activities across the Oncology Franchise.
• Designed and facilitated executive leadership forums supporting portfolio decision-making, organizational alignment, and strategic prioritization.
• Led cross-functional planning and execution activities supporting Abecma commercialization readiness and development operations.
• Directed research-stage programs through IND/CTA-enabling activities including EBV-specific cytotoxic T-lymphocyte programs.
• Managed alliance relationships and governance activities with external collaborators and strategic partners.
• Led development and implementation of integrated strategic and operational program plans across internal and external programs.
• Developed board materials, portfolio reviews, business planning analyses, and executive program updates.
• Facilitated proactive risk identification, resource planning, operational tracking, and mitigation planning across cross-functional teams.